Edwards Lifesciences Corporation $EW Shares Purchased by LRI Investments LLC

LRI Investments LLC boosted its position in Edwards Lifesciences Corporation (NYSE:EW) by 1.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,971 shares of the medical research company’s stock after buying an additional 147 shares during the quarter. LRI Investments LLC’s holdings in Edwards Lifesciences were worth $1,171,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new stake in Edwards Lifesciences in the first quarter valued at $26,000. SouthState Corp acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $27,000. Global X Japan Co. Ltd. raised its stake in shares of Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 216 shares in the last quarter. Tradewinds Capital Management LLC raised its stake in shares of Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 205 shares in the last quarter. Finally, Rossby Financial LCC acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $29,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on EW shares. Morgan Stanley upped their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Daiwa America upgraded Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 29th. Barclays increased their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 25th. Finally, Mizuho increased their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $87.06.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $74.02 on Friday. Edwards Lifesciences Corporation has a 1-year low of $64.89 and a 1-year high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $43.46 billion, a price-to-earnings ratio of 10.65, a P/E/G ratio of 3.55 and a beta of 1.05. The stock’s fifty day simple moving average is $78.09 and its 200-day simple moving average is $76.13.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the previous year, the business posted $0.70 EPS. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.